Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23491229 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL23491286 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL18968297 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL3716254 | 0.82 | EHMT2 (0.30) | — | |
| SCHEMBL2680066 | 0.82 | EHMT2 (0.30) | — | |
| SCHEMBL23491292 | 0.81 | SMN1; SMN2 (0.32) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL22880493 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL23492870 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL23492877 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL21651983 | 0.77 | SMN1; SMN2 (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-2970340-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-2158199-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| EP-1919909-A2 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | Aryx Therapeutics, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007028073-A2 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SMN1; SMN2 646/4885GNAI3 683/4885GNAO1 1172/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SMN1; SMN2 646/4885GNAI3 683/4885GNAO1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.